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“I have a dream that one day every valley shall be exalted, every 
hill and mountain shall be made low, the rough places will be 
made plains, and the crooked places will be made straight, and the 
glory of the Lord shall be revealed, and all the flesh shall see it 
together. This is our hope…”
(Martin Luther King, Washington D.C., August 28, 1963)
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Unfortunately, we are all witness to a dramatic failure in 
new, effective and possibly non-toxic therapies against 
major diseases. In fact, the diseases that were incurable 
seven decades ago remain incurable today, excluding  of 
course infectious diseases. Cancer, as well as 
neurodegenerative diseases (e.g. multiple sclerosis, 
Alzheimer’s  ) and autoimmune diseases (including 
Systemicus lupus erythematosus, rheumatoid arthritis 
and scleroderma), all suffer from poorly effective and often 
extremely toxic therapies. However, while many of these 
diseases can be controlled as chronic diseases, cancer is 
becoming a sort of nightmare rather than a disease. This is 
for two main reasons: first,   because the standard therapy 
did not show to be effective, largely under the expectancy, 
while extremely toxic and often destroying the patient’s 
body rather than helping it in defeating the disease. 
These two concepts are clearly expressed in two articles 
published in the last four years. The first one, by David 
Shaywitz and Nassim Taleb, was published in The
Financial Times in 2008 (1), and discusses the reasons for 
this dramatic failure in drug discovery. In the authors’ 
own words: “The molecular revolution was supposed to enable 
drug discovery to evolve from chance observation into rational 
design, yet dwindling pipelines threaten the survival of the 
pharmaceutical industry. What went wrong? The answer, we 
suggest, is the mismeasure of uncertainty, as academic 
researchers underestimated the fragility of their scientific 
knowledge while pharmaceuticals executives overestimated 
their ability to domesticate scientific research.” Of course, 
there is no reason not to agree with these statements. 
There is a looseness between academic science and the 
pharmas in biomedical research. There appears to be 
something like an “unrealistic ambition”: we take the 
discoveries of scientists and we apply to the concept of 
research and development the potentially applicable 
findings coming from basic research. This approach has 
not achieved innovative or effective therapies for major 
diseases. Shaywitz and Taleb write further: “For all the 
breathless headlines proclaiming breakthrough discoveries, the 
truth is that we still do not understand what causes most 
disease. Even when we can identify a responsible gene or 
implicate an important mutation, we have made only limited 
progress in turning these results into treatments.”
Unfortunately, this is the truth, and moreover it 
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represents a dramatic truth. However, I fear we have to 
seriously regard for this truth, in order to find a way to 
overcome this “big, big problem.” Another important 
point from the same article is: “Medical research is 
particularly hampered by the scarcity of good animal models for 
most human disease, as well as by the tendency of academic 
science to focus on the “bits and pieces” of life – DNA, 
proteins, cultured cells – rather than on the integrative analysis 
of entire organisms, which can be more difficult to study.”
Again, this is dramatically true. In fact, following the age 
of the big discoveries in medicine, where medical 
scientists often tested their ideas on their own bodies, 
today, biomedical research is mostly deprived of MDs or 
physicians, with positions instead filled by basic 
scientists, with no medical culture and – even worse - 
with no interest in discovery of “the causes of diseases.” 
The last point upon which I want to comment is: 
“Nevertheless, real scientific progress has occurred, inviting the 
question: why do pharmaceutical companies, which spend 
billions of dollars each year trying to turn advances into 
treatments, have so little to show for their efforts? Answer: 
spreadsheets are easy; science is hard.” I fear that the 
problem is that, during recent decades, “science” has 
become a sort of spreadsheet in its application. This is 
because the research projects in biomedicine were set up 
in a NASA-like way. Something like: “we want to get to 
the moon.” Yes; but discovery of the cause of diseases (in 
order to try to cure them) does not correspond with the 
will to get to the moon. The unforgotten genius and 1931 
Nobel Prize for Medicine, Prof. Otto H. Warburg, 
suggested to all medical scientists at the beginning of the 
last century: “We can only cure what we can understand 
first.” I think that, really, we should reset our research in 
understanding diseases. 
The example of cancer is emblematic, inasmuch as we 
continue to ignore the prime aetiology of tumours. The 
result is that, after more than 60 years from the 
introduction of chemotherapy in human beings, the gold 
standard anti-tumour strategies offered to cancer patients 
are still based on chemotherapy, surgery and 
radiotherapy, which physically try to destroy cancer with 
brute force rather than by selectively interacting with 
cancer cells’ unique biological characteristics. Actually, 
cancer represents an area with significant unmet medical 
need, with more than 20 million people worldwide being 
diagnosed annually and, despite the current available 
therapies, more than a million patients dying from this 
disease every year. There is an urgent need for safe and 
effective new treatments resulting in durable disease 
remissions and increased overall survival. At this point, I 
would like to introduce an article by Robert Gatenby (2), 
which proposes a change of strategy in the war against 
cancer. He begins by listing some facts: “The German Nobel 
laureate Paul Ehrlich introduced the concept of ‘magic bullets’ 
more than 100 years ago: compounds that could be engineered 
to selectively target and kill tumour cells or disease-causing 
organisms without affecting the normal cells in the body. The 
success of antibiotics 50 years later seemed to be a strong 
validation of Ehrlich’s idea. Indeed, so influential and enduring 
was medicine’s triumph over bacteria that the ‘war on cancer’ 
continues to be driven by the implicit assumption that magic 
bullets will one day be found for the disease.” After so many 
years, we are still waiting for this magic bullet against 
malignant tumours and, of course, this is generating the 
idea that something went wrong along the way (or from 
the very beginning). Gatenby concludes: “However, in 
battles against cancer, magic bullets may not exist and 
evolution dictates the rules of engagement.” Actually, 
Gatenby proposes that a reasonable approach may be to 
set up therapeutic strategies aimed at controlling cancer 
rather than trying to cure it, through highly toxic drug 
combinations that are seemingly more destructive to the 
patient’s body than to cancer. 
Altogether, these considerations suggest that we should 
proceed along two different - but parallel - paths in trying 
to find a way to cure diseases while at the same time 
avoiding treatments that are needlessly aggressive for the 
patient’s body (being extremely toxic and poorly 
effective). For this purpose, I would like to come back to a 
concept which in the past had a pivotal role in the 
identification of drugs proven effective in different 
diseases, namely ‘serendipity’. 
Today, the word ‘serendipity’ is used in everyday 
language, though with different definitions, such as “the 
faculty of making happy and unexpected discoveries by 
accident,” and “the faculty of finding valuable or 
agreeable things not sought for” and “an accidental 
discovery” (i.e., “finding one thing while looking for 
something else”). However, the word itself has a very 
ancient origin. In fact, serendip was the old Arabic name 
for Ceylon, now known as Sri Lanka. The real origin of 
the word ‘serendipity’ comes from a Persian fairy tale 
telling of the Three Princes of Serendip who, during their 
travels, accidentally discovered numerous things they 
were not in fact on a quest for. In the 16th century, the 
tale was translated from Persian to Italian, and from 
Italian to French. Horace Walpole (1717-1797), an English 
man of letters, encountered it in a collection of oriental 
tales in French, and coined the English term ‘serendipity’ 
in a letter to his friend, Horace Mann, dated June 28, 1754. 
We should not forget that serendipity is one of the pivotal 
factors contributing to drug discovery. Whether we want 
to keep the definition whereby serendipity implies the 
finding of one thing while looking for something else, we 
should recall the discovery of penicillin first. Fleming was 
studying “staphylococcus influenza” when one of his 
culture plates had become contaminated, developing a 
mould that created a bacteria-free circle. Later, he found
within the mould a substance that has highly resistant 
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against the vast majority of bacteria infecting human 
beings. Equally, serendipity played a key role in the 
discovery of a wide range of psychotropic drugs, 
including aniline purple, lysergic acid diethylamide, 
meprobamate, chlorpromazine and imipramine (3). It 
appears quite clear that, at least in the past, serendipity 
played a pivotal role drug discoveries – or, more 
precisely, in the discovery of drugs that were effective 
against different diseases. Thus, while we are confronted 
with an unbelievable failure in the discovery of effective 
drugs based on cross-communication between basic 
science and drug companies, we have to realize that this 
approach should be abandoned if we want to get to better 
results. Probably, we should have another look at the 
thousands of drugs on the market with different eyes. 
Probably, we would be better to think of the ‘off-
targeting’ of drugs. In fact, there is an interesting 
approach using side-effects’ similarities for drug target 
identification, meaning that there is a trend in drug 
discovery based on the identification of common off-
targets of different drugs through the evidence of 
common side effects (4). An example of the off-targeting 
approach comprises proton pump inhibitors, which in 
addition to having some off-targets in the central nervous 
system (4) have also been shown to have a potent anti-
tumour effect, through the inhibition of proton pumps on 
tumour cells (which are similar, but not identical, to 
gastric proton pumps (5-10)).  
However, in addition to thinking about the careful 
identification of effective off-targeting drugs, we should 
also think about different systems of drug delivery. In the 
strategic platforms for nanomedicine, it is clearly stated 
that nanomedicine seeks to exploit the improved (and 
often novel) physical, chemical and biological properties 
of materials at the nanometric scale. However, these 
documents specify that there is an urgent need for 
biomimetism, namely the process of simulating what 
occurs in nature. Exosomes are nanovesicles, naturally 
released from almost every cell in our body and which, 
whether in a normal or a diseased state, deliver a mess of 
molecules including proteins, lipids and nucleic acids. 
They are able to interact with the target cells within an 
organ or at distance using different mechanisms, 
including ligand-to-receptor interaction (11-12) and 
fusion with the cell plasma membrane via the transfer of 
their contents within the cell cytoplasm (13). Thus, 
exosomes appear as a vectorized signalling system 
operating inside a donor cell by  either binding to the 
membrane receptors or directly interacting with  internal 
compartments of the target cell. These notions place the 
exosome at the centre of the real novelties in translational 
science, and mark it as a potential candidate autologous 
nanoshuttles for drugs potentially useful for the future 
strategies in nanomedicine. The future use of exosomes 
for new therapeutic and diagnostic approaches has to be 
discussed and given serious consideration. Exosomes are 
becoming the real novelty in the identification of novel 
biomarkers. In fact, new tests offering the possibility of 
the contemporary characterization and quantification of 
exosomes in human body fluid have been set up recently 
(14). This dual potentiality of the exosome recommends 
the use of these nanovesicles as the ideal tool in 
‘theranostics’. This new area of nanomedicine focuses on 
multi-disciplinary research to build new systems for 
various nanobiomedical applications, ranging from the 
medical use of nanoplatform-based diagnostic agents, to 
therapeutic agents and even possible future applications 
of diagnosis and therapy - theranostics. Theranostics is 
the medical application of nanobiotechnology and refers 
to highly specific medical intervention at the nanoscale in 
diagnosing, curing and preventing diseases. It includes 
the early detection of diseases, the monitoring of 
therapeutic responses and the targeted delivery of 
therapeutic agents. Theranostics at the nanometric-scale 
encompasses, nanoprobes, nanocarriers and 
nanodiagnostics. However, the most important task of a 
theranostic strategy concerns theranostic 
nanoformulations, which deal with the development of 
new agents based on a ‘whole in one approach’ that 
should have its maximal application in the field of 
personalized medicine.. The exosome appears as the ideal 
nanovector for theranostics, with maximal potentiality for 
targeting the disease site with only minimal side effects. If 
successful, the proof-of-concept in the use of exosomes as 
the autologous nanovector for both the diagnosis and 
therapy of major diseases will allow for widespread 
preclinical and clinical applications. 
I have a dream, as well: “that serendipity, ideas and an 
open mind, will drive new research in biomedicine, 
acquiring the best results with the aim of freeing human 
beings from the nightmare of uncurable diseases”  
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